Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial
October 17, 2024 08:00 ET
|
Immutep Limited
Media Release First safety data anticipated before year end with assessment of PK/PD relationships to follow in H1’CY2025 SYDNEY, AUSTRALIA, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:...
Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit
October 10, 2024 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer
October 03, 2024 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel...
Immutep Receives A$3.6 million R&D Tax Incentive from French Government
September 24, 2024 08:00 ET
|
Immutep Limited
Media Release SYDNEY, AUSTRALIA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel LAG-3 related...
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
September 18, 2024 08:00 ET
|
Immutep Limited
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society 2024 Annual MeetingEFTISARC-NEO is the first trial to...
Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer
September 16, 2024 08:00 ET
|
Immutep Limited
Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in...
Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024
August 20, 2024 08:00 ET
|
Immutep Limited
Media Release Oral presentation will detail results from the randomized TACTI-003 Phase IIb trial in first line head & neck squamous cell carcinoma patients with any PD-L1 expression (CPS >1) ...
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody
August 14, 2024 08:00 ET
|
Immutep Limited
Media Release IMP761 is designed to enhance the “brake” function of LAG-3 on T cells to restore balance to the immune system and address the underlying cause of many autoimmune diseasesSafety data...
Immutep to Participate in Upcoming Investor Conferences
August 07, 2024 08:00 ET
|
Immutep Limited
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...
Immutep Quarterly Activities Report Q4 FY24
July 31, 2024 08:00 ET
|
Immutep Limited
Media Release Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA®...